Zilucoplan
FDA-approved under-the-skin C5 inhibitor for gMG (Zilbrysq).
Ref $ —reference only
ZilucoplanFDA-approvedWhat it's for
FDA-approved under-the-skin C5 inhibitor for gMG (Zilbrysq).
What it's for
Zilucoplan is a macrocyclic peptide that binds complement component C5. It treats generalized myasthenia gravis in anti-AChR antibody–positive adults.
What it does for the body
It treats generalized myasthenia gravis in anti-AChR antibody–positive adults. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Blocking C5 cleavage prevents membrane-attack complex formation that damages meeting points between nerves and muscles in AChR+ MG. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Zilucoplan has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Bones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Zilucoplan — FDA.gov search
- ClinicalTrials.gov search: Zilucoplan — U.S. clinical trials registry
- Drugs@FDA search: Zilucoplan — FDA drug database (if approved)
- PubMed search: Zilucoplan — NCBI PubMed
- PubMed Central search: Zilucoplan — NCBI PMC
Reference
No ref on file.